Oprozomib (ONX 0912)
99%
- Product Code: 62106
CAS:
935888-69-0
| Molecular Weight: | 532.61 g./mol | Molecular Formula: | C₂₅H₃₂N₄O₇S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD25976563 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Oprozomib (ONX 0912) is primarily used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It works by inhibiting the proteasome, a complex that breaks down proteins in cells, leading to the accumulation of damaged or misfolded proteins. This accumulation triggers cell death, particularly in cancer cells, which are more reliant on the proteasome for survival. Oprozomib is often considered for patients who have not responded well to other treatments or have relapsed after initial therapy. It is administered orally, offering a convenient alternative to intravenous proteasome inhibitors. Clinical trials have explored its efficacy both as a monotherapy and in combination with other anticancer agents, showing promise in improving patient outcomes. Its development represents an advancement in targeted cancer therapies, particularly for refractory or relapsed cases.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $109.47 |
+
-
|
Oprozomib (ONX 0912)
Oprozomib (ONX 0912) is primarily used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It works by inhibiting the proteasome, a complex that breaks down proteins in cells, leading to the accumulation of damaged or misfolded proteins. This accumulation triggers cell death, particularly in cancer cells, which are more reliant on the proteasome for survival. Oprozomib is often considered for patients who have not responded well to other treatments or have relapsed after initial therapy. It is administered orally, offering a convenient alternative to intravenous proteasome inhibitors. Clinical trials have explored its efficacy both as a monotherapy and in combination with other anticancer agents, showing promise in improving patient outcomes. Its development represents an advancement in targeted cancer therapies, particularly for refractory or relapsed cases.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :